| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H19N3O5 |
| Molecular Weight | 333.3392 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@H](CCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O)C(O)=O
InChI
InChIKey=CATMPQFFVNKDEY-YPMHNXCESA-N
InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13+/m1/s1
| Molecular Formula | C16H19N3O5 |
| Molecular Weight | 333.3392 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Golotimod (SCV-07) is compound that has been investigated as a medicine for the treatment of tuberculosis, and various other viral and bacterial infections. Golotimod acts broadly on the Toll-like receptor (TLR) pathway. It stimulates the T-helper 1 (Th1) type immune response and blocks signal transducers and activator of transcription 3 (STAT3) mediated signaling. Treatment of tuberculosis with golotimod improves clearance of mycobacteria, cavity healing, and immune parameters and also reduced symptoms (such as fever, weakness, sweating, dry cough, productive cough, dyspnea, chest pain, tachycardia) without adverse effects. Phase II clinical trials have been completed to assess its safety and tolerability.
